BMS/AZ's Forxiga joins rivals on German diabetes scrap heap
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and AstraZeneca are the latest to join the growing club of companies withdrawing their drugs in Germany due to pricing and reimbursement difficulties. The two pharma majors have removed their diabetes drug Forxiga (dapagliflozin) from the German market pending the outcome of an arbitration procedure which is likely to grant the product a price in line with cheap sulfonylureas. Forxiga is just the latest diabetes casualty, following in the wake of Boehringer Ingelheim/ Lilly’s Tradjenta (linagliptin) and Novo Nordisk’s Tresiba (insulin degludec).